KE
Therapeutic Areas
Aspira Women's Health Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OvaWatch | Longitudinal risk monitoring of indeterminate/benign adnexal masses | Commercial |
| Ova1Plus | Pre-surgical risk assessment of adnexal masses (reflex protocol) | Commercial |
| Ova1 | Pre-surgical risk assessment of adnexal masses | Commercial |
| Overa | Pre-surgical risk assessment (reflex test) | Commercial |
| Next-Gen Biomarker Discovery | Improved ovarian cancer detection | Research |
Leadership Team at Aspira Women's Health
NS
Nicole Sandford
President and CEO
RG
Robert G. Bullock
Key Scientific Leader/R&D (inferred from publications)